SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavaxs sharp selloff has traders weighing Shah Capitals move away from activism and disclosed share sale, Citis reiterated Sell rating, and weakness across biotech stocks. A resurfaced TipRanks report alleging an FDA hold also drew attention, but many traders said it recycled a resolved 2024 event; claims that it or trading activity deliberately drove the decline remain disputed.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET is drawing attention amid a sharp selloff in AI and semiconductor stocks, alongside concerns that its optical-interposer technology has yet to translate into verified, scaled sales. Traders are split on whether Lumilens-related qualification and production chatter and NVIDIA-Ciscos new pluggable-optics push validate POETs opportunity or underscore execution and competitive risks, with the upcoming quarterly report viewed as a key check-in.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys upcoming Q3 results are the main focus after a sharp pullback amid a broader selloff in AI and growth stocks. Traders are split between expecting strong results to revive the shares and warning that high expectations and valuation could fuel a sell-the-news reaction.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabets upcoming earnings are drawing attention, with traders watching Google Cloud growth and Geminis AI monetization against concerns that rising AI capital spending may weigh on returns. The discussion is divided between buyers expecting strong results and a rebound, and skeptics focused on the stocks recent weakness and possible further declines.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs sharp selloff and prolonged losing streak are fueling debate over why it is lagging Bitcoin, with traders pointing to concerns about Bitcoin sales, weak financials, and an AI/data-center pivot that still lacks signed tenant leases. Some see an oversold bounce or short squeeze setup, while others remain bearish on the companys execution and outlook.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is drawing attention amid sharp swings in South Korean equities, with weakness in chip-heavy Samsung and SK Hynix shares and concerns about AI and memory-stock sentiment weighing on the fund. Traders are divided between buying an oversold rebound and warning that its 3x daily leverage can amplify further losses and decay.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is drawing attention after a sharp price and volume surge, with traders speculating about an undisclosed catalyst and pointing to the Flexa/Anvil payments thesis. Others argue the move may be another short-lived pump, and no specific new development is confirmed in the discussion.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Traders are positioning ahead of Robloxs upcoming earnings, with the discussion focused on whether engagement and bookings can support a recovery. Bulls point to recent buying and a defended technical base, while bears remain concerned about slowing growth and the earlier analyst downgrade; sentiment is divided.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are drawing attention after a steep selloff, with traders focused on staggered IPO lockup expirations that make more shares eligible for sale, alongside weakness across AI and semiconductor stocks. Bears cite valuation, potential share supply, and concerns about growth and customer concentration, while bulls argue the stock is oversold and are buying the decline.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

ARKK is drawing attention after a sharp pullback and a test of support near the $80 level. Traders are split between expecting a bounce if support holds and warning that the funds volatile holdings and Cathie Woods criticized track record leave room for further weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cytokinetics Q2 2026 Earnings Call: Complete Transcript

On Thursday, Cytokinetics (NASDAQ:CYTK) discussed second-quarter financial results during its earnings call. The full transcript is provided below.
This content is powered by Benzinga APIs. For comprehensive financialread more...

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist 

Equity

JNJ reports third-quarter results on Tuesday, and Koyfin analysts expect modest revenue growth and lower earnings.

Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?

Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.

Here's How Much You Would Have Made Owning Cytokinetics Stock In The Last 15 Years

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 15 years by 2.64% on an annualized basis producing an average annual return of 15.99%. Currently, Cytokinetics has a market capitalization of $9.70read more...

If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 10.3% on an annualized basis producing an average annual return of 23.89%. Currently, Cytokinetics has a market capitalization of $10.16read more...

Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? 

Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.

Cytokinetics Investors Weigh Safety Data From Pivotal Trial

Cytokinetics reports Phase 3 results for aficamten in treating hypertrophic cardiomyopathy, targeting a Q4 FDA submission.read more...

If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.78% on an annualized basis producing an average annual return of 21.28%. Currently, Cytokinetics has a market capitalization of $10.34read more...

Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?

BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs.

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Cytokinetics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CYTK News